Jade Biosciences, Inc.
NASDAQ:JBIOBiotechnology
-$0.21 today
- Market cap
- $1.07B
- Beta
- 1.45
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$2.24
Volume 0.79M
Average 0.83M
JBIO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Jade Biosciences, Inc.NASDAQ: JBIO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $7.38M rose 118.2% year over year, ahead of the +68.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 14.7% from the prior quarter. Over 3 fiscal years it compounded at +12.0% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -3.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $7.38M+14.7% QoQ
- Last fiscal yearDec 2025
- $20.42M-3.3% YoY
- LTMMar 2026
- $24.44M+68.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +118.2% | -100.0% | -218.2 pp |
| 1 year | -3.3% | -100.0% | -96.7 pp |
| 3-year CAGR | +12.0% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 20.42M USD
- Year-over-year change
- -3.3%
- 4-year CAGR
- +26.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.42M | -3.3% |
| FY2024 | 2024-12-31 | 21.13M | +23.6% |
| FY2023 | 2023-12-31 | 17.09M | +17.5% |
| FY2022 | 2022-12-31 | 14.55M | +81.4% |
| FY2021 | 2021-12-31 | 8.02M | — |
Selling, General & Admin vs competitors
How JBIO compares with its peers on the latest reported figures
- JBIO's LTM Mar 2026 selling, general & admin of $24.44M is the 5th highest of the 9 companies compared; the peer median is $30M.
- Its year-over-year change of +68.3% is the 2nd highest of 9, against a peer median of +18.5%.
- Over three fiscal years its annual growth of +12.0% compares with a peer median of +22.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $153.89M | +144.6% | +66.0% | — | |
| LTM Mar 2026 | $46.46M | +34.5% | +22.2% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $39.39M | +37.0% | — | — |
| LTM Mar 2026 | $37.43M | +18.7% | +65.2% | — | |
| LTM Mar 2026 | $24.44M | +68.3% | +12.0% | — | |
| LTM Mar 2026 | $22.58M | +5.5% | -4.4% | 269.8% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $17.4M | +18.2% | +41.6% | — |
| LTM Mar 2026 | $16.54M | -15.6% | +10.2% | — | |
| LTM Mar 2026 | $6.52M | -33.0% | +12.9% | — | |
| Peer median (excluding JBIO) | $30M | +18.5% | +22.2% | 269.8% | |
Competitors are the stored peer set for JBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 15K | 68K | 96K | 282K | 0 |
| Gross Profit | (15K) | (68K) | (96K) | (282K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 14.99M | 38.62M | 64.22M | 53.19M | 93.12M |
| Selling, General & Admin | 8.02M | 14.55M | 17.09M | 21.13M | 20.42M |
| Operating Expenses | 23.01M | 53.17M | 81.31M | 74.31M | 113.54M |
| Depreciation & Amortization | 15K | 68K | 96K | 282K | 26K |
| EBITDA | (22.95M) | (51.42M) | (75.37M) | (69.29M) | (127.33M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (23.02M) | (53.24M) | (81.41M) | (74.6M) | (113.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 65K | 1.83M | 5.95M | 5.04M | 7.78M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 62K | 1.75M | 5.94M | 5.02M | (13.81M) |
| Income Before Tax | (22.96M) | (51.49M) | (75.47M) | (69.57M) | (127.35M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 3K | 25K | 56K | 55K | 58K |
| Net Income | (22.96M) | (51.51M) | (75.52M) | (69.63M) | (127.41M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (32.96) | (73.67) | (100.38) | (85.26) | (4.06) |
| EPS (Diluted) | (32.96) | (73.67) | (100.38) | (85.26) | (4.06) |
| Weighted Avg Shares | 697.44K | 699.2K | 752.33K | 816.63K | 31.36M |
| Weighted Avg Shares (Diluted) | 697.44K | 699.2K | 752.33K | 816.63K | 31.36M |
Jade Biosciences, Inc.
NASDAQ:JBIO
Intrinsic Alpha fair value
Locked
Current Price
$15.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.